Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Escitalopram the S-enantiomer of the racemate citalopram, is clinically more effective than citalopram in the treatment of major depressive disorder. However, the precise mechanism by which escitalopram achieves superiority over citalopram is yet to be determined. It has been hypothesized that the therapeutically inactive R-enantiomer competes with the serotonin-enhancing S-enantiomer at a low-affinity allosteric site on serotonin reuptake transporters (SERTs), and reduces the effectiveness of the S-enantiomer at the primary, high-affinity serotonin-binding site. This study summarizes the results of two recent single-photon emission computerized tomography studies measuring SERT occupancy in citalopram-treated and escitalopram-treated healthy volunteers, after a single dose and multiple doses (i.e. under steady-state conditions). The single-dose study showed no attenuating effect of R-citalopram. After multiple dosing, however, SERT occupancy was significantly reduced in the presence of R-citalopram. Under steady-state conditions, R-enantiomer concentrations were greater than for the S-enantiomer because of slower clearance of R-citalopram. A pooled analysis suggests that build-up of the R-enantiomer after repeated citalopram dosing may lead to increased inhibition of S-enantiomer occupancy of SERT. This review adds to the growing body of evidence regarding differences in the dynamics of SERT occupancy, that is, molecular mechanisms underlying the often-observed superior clinical efficacy of escitalopram compared with citalopram in major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 5×
“Instead, the ability of SSRIs to penetrate the brain and accumulate around the synapses and axons, where SERTs are found in abundance (Zhou et al., 1998), was proposed as an important factor in predicting occupancy (Meyer et al., 2004).”
BackgroundResultInfluentialDysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm
Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., Wilson, A. A., Blak, T., Eynan-Harvey, R., Goulding, V. S., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.90 · Cited by 264 · cited 4×
“…including major depressive disorder (MDD) (Kasper et al., 1990; Meyer et al., 2003), with or without dysfunctional attitudes, for example, self-injurious behaviour (Meyer et al., 2003), anxiety disorders (Neumeister et al., 2004; Lanzenberger et al., 2007) and schizophrenia (Kasper et al., 2002).”
BackgroundInfluentialLepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Regional distribution of serotonin transporter protein in postmortem human brain
Kish, S. J., Furukawa, Y., Chang, L.-J., Tong, J., Ginovart, N., Wilson, A., Houle, S., & Meyer, J. H. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.10.001 · Cited by 179
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Self-citationKlein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0486-0 · Cited by 77 · cited 6×
“This study discusses the results of two recent studies that measured SERT occupancy in healthy young men given escitalopram or citalopram, and relates the findings to differences in clinical efficacy between these two preparations (Klein et al., 2006, 2007).”
BackgroundMethodResultInfluentialSelf-citationKlein, N., Sacher, J., Geiss-Granadia, T., Mossaheb, N., Attarbaschi, T., Lanzenberger, R., Spindelegger, C., Holik, A., Asenbaum, S., Dudczak, R., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0666-y · Cited by 62 · cited 8×
“This study discusses the results of two recent studies that measured SERT occupancy in healthy young men given escitalopram or citalopram, and relates the findings to differences in clinical efficacy between these two preparations (Klein et al., 2006, 2007).”
BackgroundMethodResultInfluentialSelf-citation
Cited by
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“…published evidence from preclinical in-vitro and in-vivo pharmacology studies (e.g. Sanchez and Meier, 1997) and clinical efficacy studies (Montgomery et al., 2007; Rao, 2007; Kasper et al., 2009b; Montgomery and Moller, 2009) that would support meaningful differences among SSRIs in their effects.”
BackgroundMethodResultInfluentialSerotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113
Self-citationWindischberger, C., Lanzenberger, R., Holik, A., Spindelegger, C., Stein, P., Moser, U., Gerstl, F., Fink, M., Moser, E., & Kasper, S. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.013 · Cited by 114
Self-citationZhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
“The list is not intended to be exhaustive and the authors apologize for not being able to include additional references due to space limitations methyl)phenyl]thio)-5-[123I]-iodophenylamine) in singlephoton emission computerized tomography (SPECT) studies (Kasper et al. 2009b).”
Baldinger, P., Kranz, G. S., Haeusler, D., Savli, M., Spies, M., Philippe, C., Hahn, A., Höflich, A., Wadsak, W., Mitterhauser, M., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.002 · Cited by 67
Self-citationEscitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Kraus, C., Ganger, S., Losak, J., Hahn, A., Savli, M., Kranz, G. S., Baldinger, P., Windischberger, C., Kasper, S., & Lanzenberger, R. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.036 · Cited by 54
Self-citation
Metadata
- Authors
- Kasper, S., Sacher, J., Klein, N., Mossaheb, N., Attarbaschi-Steiner, T., Lanzenberger, R., Spindelegger, C., Asenbaum, S., Holik, A., & Dudczak, R.
- Venue
- International Clinical Psychopharmacology
- Published
- 2009-05
- Volume
- 24
- Issue
- 3
- Pages
- 119-125
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2070055903
- Cited by
- 57
- References
- 8
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.